Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database.
The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery.



The records of 274 patients with pRCC in the Korean renal cell carcinoma (KORCC) database were included for evaluation. Of the 274 patients, 118 had type 1 pRCC and 156 had type 2 pRCC. The patient characteristics, including clinicopathologic parameters, were investigated, and the oncologic outcomes were evaluated.



The mean patient age was significantly older in the type 2 pRCC group. Compared with type 1 pRCC tumors, type 2 pRCC tumors were more often localized to the renal hilum (P = .030). Patients with type 2 pRCC had a greater incidence of Fuhrman grade 3 and 4 tumors than those with type 1 pRCC (78.8% vs. 22.8; P < .001). Tumor necrosis and capsular invasion were more frequently found in type 2 pRCC (P = .008 and P = .007, respectively). At a mean follow-up period of 38.0 months (interquartile range, 11.8-57.3 months), the subclassification of pRCC did not influence the prognosis of patients with pRCC.



From the information available in the KORCC database, we identified significant differences in clinicopathologic variables, including age, Fuhrman grade, tumor location, tumor necrosis, and capsular invasion between type 1 and 2 pRCC. Although type 2 pRCC had more aggressive clinicopathologic characteristics, subclassification of pRCC did not affect the oncologic outcomes.
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Yun-Sok
YS
Ha
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Jae-Wook
JW
Chung
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Seock Hwan
SH
Choi
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Jun Nyung
JN
Lee
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Hyun Tae
HT
Kim
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Tae-Hwan
TH
Kim
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea.
Sung Kwang
SK
Chung
Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Seok-Soo
SS
Byun
Department of Urology, Chonnam National University Hwasun Hospital, Jeonnam, Korea.
Eu Chang
EC
Hwang
Department of Urology, Korea University School of Medicine, Seoul, Korea.
Seok Ho
SH
Kang
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sung-Hoo
SH
Hong
Department of Urology, National Cancer Center, Goyang, Korea.
Jinsoo
J
Chung
Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
Cheol
C
Kwak
Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea.
Yong-June
YJ
Kim
Department of Urology, Kyungpook National University Medical Center, Daegu, Korea. Electronic address: tgkwon@knu.ac.kr.
Tae Gyun
TG
Kwon
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000145:classification*; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000145:classification*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D056910:Republic of Korea
KORCC database; Nephrectomy; Prognosis; T stage; pRCC